Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2020 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at the SVB Leerink 9th Annual Global Healthcare Conference

BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
February 25, 2020 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million

-- Paratek Expects Full Year 2020 Total Revenues to be Between $75 and $80 Million including NUZYRA Net Sales of Approximately $66 Million -- Paratek Now Anticipates its Cash Runway Will Extend...
February 24, 2020 07:00 ET | Source: Paratek Pharmaceuticals

Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region

BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
February 13, 2020 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020

BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
December 18, 2019 17:12 ET | Source: Paratek Pharmaceuticals

Paratek Awarded BARDA Project BioShield Contract for NUZYRA®

- Total award valued at up to $285 million - Paratek to host a conference call today, December 18, 2019 at 5:30 p.m. EST BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc....
December 02, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
November 12, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019

-- Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million -- -- Oral-only CABP Pharmacokinetics Study Initiated-- BOSTON, Nov. 12, 2019 (GLOBE...
November 04, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019

BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
November 01, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
October 31, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections

BOSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...